Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 4Terminated 1

Sponsor Class

INDUSTRY 5OTHER 3NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Genitourinary 1

Conditions

Thrombocythemia, Essential 1Prostatic Neoplasms 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × lestaurtinib × Clear all
NCT00079482 2016-07-21

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
224 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00586651 2015-10-08

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
39 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT00081601 2012-08-24

Study of CEP-701 in Treatment of Prostate Cancer

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT00030186 2012-08-23

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
37 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT00242827 2012-08-23

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡